Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SANOBER KABLE

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1295876399
CMS profile
331455
Location
DENISON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$32,971.88

287 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 5 of 6; records 201–250 of 287 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SANOBER KABLE

NPI 1295876399 · CMS profile ID 331455

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

DENISON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 6; records 201–250 of 287 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295876399?year=2021&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SANOBER KABLE, NPI 1295876399, CMS profile ID 331455. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 287 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295876399?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). SANOBER KABLE, NPI 1295876399, CMS profile ID 331455. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 287 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295876399?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
SANOBER KABLE, NPI 1295876399, CMS profile ID 331455, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 6; records 201–250 of 287 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1295876399?year=2021&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

287 matching records · $32,971.88 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 287 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 287.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $20.3904/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763540186 CMS
JAZZ PHARMACEUTICALS INC. $25.0004/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845549959 CMS
Electromed, Inc. $8.8704/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849607329 CMS
JAZZ PHARMACEUTICALS INC. $9.4404/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845586467 CMS
GlaxoSmithKline, LLC. $1,200.0004/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802944981 CMS
Grifols USA, LLC $16.8104/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846763535 CMS
United Therapeutics Corporation $1,435.0004/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839136685 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $25.8004/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763540188 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.2004/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763540190 CMS
Mylan Specialty L.P. $10.4504/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965410685 CMS
Takeda Pharmaceuticals U.S.A., Inc. $10.7104/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820003517 CMS
GlaxoSmithKline, LLC. $0.7804/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801669169 CMS
GlaxoSmithKline, LLC. $4.4904/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803050616 CMS
Grifols USA, LLC $16.5404/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846780555 CMS
JAZZ PHARMACEUTICALS INC. $5.2404/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845579827 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $13.0704/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763540192 CMS
Electromed, Inc. $12.9504/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849607331 CMS
GlaxoSmithKline, LLC. $11.2304/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802044187 CMS
Actelion Pharmaceuticals US, Inc. $20.1604/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788088891 CMS
Mylan Specialty L.P. $4.6704/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965409003 CMS
GlaxoSmithKline, LLC. $9.7104/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801673711 CMS
Novartis Pharmaceuticals Corporation $15.2803/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812737765 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.1303/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763540194 CMS
Sunovion Pharmaceuticals Inc. $9.3403/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821898175 CMS
GlaxoSmithKline, LLC. $11.1303/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801907043 CMS
GlaxoSmithKline, LLC. $14.5003/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802978793 CMS
GlaxoSmithKline, LLC. $8.4303/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801670639 CMS
Regeneron Healthcare Solutions, Inc. $18.5003/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809590943 CMS
GlaxoSmithKline, LLC. $4.2303/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801670477 CMS
Mylan Specialty L.P. $11.0603/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965407329 CMS
Electromed, Inc. $11.0703/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849607325 CMS
GENZYME CORPORATION $19.3303/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843614987 CMS
Actelion Pharmaceuticals US, Inc. $20.9003/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788088889 CMS
GlaxoSmithKline, LLC. $6.2003/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802948497 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.5803/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763540196 CMS
Bayer HealthCare Pharmaceuticals Inc. $19.3203/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789095503 CMS
Sunovion Pharmaceuticals Inc. $19.1103/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821685177 CMS
JAZZ PHARMACEUTICALS INC. $23.1703/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845588567 CMS
Electromed, Inc. $9.4403/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849607323 CMS
GlaxoSmithKline, LLC. $4.8103/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119249374 CMS
Sunovion Pharmaceuticals Inc. $17.9703/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821722257 CMS
Sunovion Pharmaceuticals Inc. $5.0003/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821928153 CMS
Mylan Specialty L.P. $8.1503/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965404077 CMS
JAZZ PHARMACEUTICALS INC. $4.9602/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845579825 CMS
Actelion Pharmaceuticals US, Inc. $26.4902/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788088895 CMS
GlaxoSmithKline, LLC. $7.3302/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802920149 CMS
Regeneron Healthcare Solutions, Inc. $20.9002/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809590941 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $10.9502/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763540198 CMS
AstraZeneca Pharmaceuticals LP $12.6102/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834346359 CMS
Electromed, Inc. $7.7602/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849607317 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $21,755.39 278
PY2020 $27,550.20 312
PY2021 $32,971.88 287
PY2022 $26,478.39 229
PY2023 $38,541.54 113
PY2024 $52,440.29 166
PY2025 $29,030.83 192

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $130,712.81 58
PY2024 Principal investigator $400,767.02 106
PY2023 Principal investigator $116,399.43 34
PY2022 Principal investigator $17,554.61 6
PY2021 Principal investigator $15,782.65 3
PY2019 Recipient $1,400.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

58 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114.00 12/19/2025 Non-covered Recipient Entity
PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184278236
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114.00 12/19/2025 Non-covered Recipient Entity
PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184278238
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114.00 12/19/2025 Non-covered Recipient Entity
PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184278240
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114.00 12/19/2025 Non-covered Recipient Entity
PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184278242
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114.00 12/19/2025 Non-covered Recipient Entity
PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184278244
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114.00 12/19/2025 Non-covered Recipient Entity
PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184278246
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114.00 12/19/2025 Non-covered Recipient Entity
PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184278248
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114.00 12/19/2025 Non-covered Recipient Entity
PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184278250
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114.00 12/19/2025 Non-covered Recipient Entity
PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184278252
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114.00 12/19/2025 Non-covered Recipient Entity
PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184278254
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114.00 12/19/2025 Non-covered Recipient Entity
PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184278256
Principal investigator 1 Insmed, Inc. $977.60 11/14/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648438
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,000.00 10/30/2025 Non-covered Recipient Entity
PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184256143
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 10/30/2025 Non-covered Recipient Entity
PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184256145
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,200.00 10/30/2025 Non-covered Recipient Entity
PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184256147
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.21 10/23/2025 Non-covered Recipient Entity
PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184253138
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42.19 10/23/2025 Non-covered Recipient Entity
PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184253140
Principal investigator 1 SANOFI US SERVICES INC. $16,000.00 10/22/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine Pa
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype No dispute reported 06/30/2026 1226104865
Principal investigator 1 Insmed, Inc. $9,998.82 10/17/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648440
Principal investigator 1 United Therapeutics Corporation $3,331.65 10/06/2025 Non-covered Recipient Entity
Premier Pulmonary cc and sleep Medicine
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242387569
Principal investigator 1 AstraZeneca Pharmaceuticals LP $301.61 07/16/2025 Non-covered Recipient Entity
PREMIER PULMONARY
A Randomised, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy No dispute reported 06/30/2026 1185545211
Principal investigator 1 United Therapeutics Corporation $1,500.00 07/04/2025 Non-covered Recipient Entity
Premier Pulmonary cc and sleep Medicine
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242387567
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,567.15 06/23/2025 Non-covered Recipient Entity
CARDIOVOYAGE LLC
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185545213
Principal investigator 1 Cumberland Pharmaceuticals, Inc. $12,228.75 06/10/2025 Non-covered Recipient Entity
PREMIER PULMONARY CRITICAL CARE & SLEEP MEDICINE
ORAL IFETROBAN IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) No dispute reported 06/30/2026 1242141379
Principal investigator 1 Cumberland Pharmaceuticals, Inc. $13,350.00 06/10/2025 Non-covered Recipient Entity
PREMIER PULMONARY CRITICAL CARE & SLEEP MEDICINE
ORAL IFETROBAN IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) No dispute reported 06/30/2026 1242141383
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,510.00 04/28/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine Admin
BAY 632521, RiOciguAt UseRs Registry The ROAR registry No dispute reported 06/30/2026 1225419861
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,590.00 04/28/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine Admin
BAY 632521, RiOciguAt UseRs Registry The ROAR registry No dispute reported 06/30/2026 1225419875
Principal investigator 1 Insmed, Inc. $870.48 03/31/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648434
Principal investigator 1 Insmed, Inc. $209.43 03/31/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648436
Principal investigator 1 Insmed, Inc. $0.22 03/19/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648390
Principal investigator 1 Insmed, Inc. $1.38 03/19/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648398
Principal investigator 1 Insmed, Inc. $1.38 03/19/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648404
Principal investigator 1 Insmed, Inc. $6,888.84 03/17/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648394
Principal investigator 1 Insmed, Inc. $0.46 03/17/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648400
Principal investigator 1 Insmed, Inc. $0.92 03/17/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648406
Principal investigator 1 Insmed, Inc. $1,251.90 02/21/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648408
Principal investigator 1 Insmed, Inc. $1,210.95 02/21/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648410
Principal investigator 1 Insmed, Inc. $1,088.10 02/21/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648412
Principal investigator 1 Insmed, Inc. $1,088.10 02/21/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648414
Principal investigator 1 Insmed, Inc. $209.43 02/21/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648416
Principal investigator 1 Insmed, Inc. $152.10 02/21/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648418
Principal investigator 1 Insmed, Inc. $209.43 02/21/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648420
Principal investigator 1 Insmed, Inc. $209.43 02/21/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648422
Principal investigator 1 Insmed, Inc. $42.12 02/21/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648424
Principal investigator 1 Insmed, Inc. $152.10 02/21/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648426
Principal investigator 1 Insmed, Inc. $152.10 02/21/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648428
Principal investigator 1 Insmed, Inc. $152.10 02/21/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648430
Principal investigator 1 Insmed, Inc. $40.95 02/21/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648432
Principal investigator 1 GlaxoSmithKline, LLC. $7,500.00 01/28/2025 Non-covered Recipient Entity
PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE
A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR No dispute reported 06/30/2026 1192169587
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 01/28/2025 Non-covered Recipient Entity
PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE
A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR No dispute reported 06/30/2026 1192169591
Principal investigator 1 Insmed, Inc. $0.66 01/16/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648386
Principal investigator 1 Insmed, Inc. $9,185.12 01/16/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648392
Principal investigator 1 Insmed, Inc. $0.46 01/16/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648396
Principal investigator 1 Insmed, Inc. $1.38 01/16/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648402
Principal investigator 1 Insmed, Inc. $0.88 01/13/2025 Non-covered Recipient Entity
Premier Pulmonary Critical Care And Sleep Medicine PA
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189648388
Principal investigator 1 United Therapeutics Corporation $1,500.00 01/09/2025 Non-covered Recipient Entity
Premier Pulmonary cc and sleep Medicine
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242387565
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,711.41 01/08/2025 Non-covered Recipient Entity
PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185545209
Principal investigator 1 Cumberland Pharmaceuticals, Inc. $7,500.00 01/03/2025 Non-covered Recipient Entity
PREMIER PULMONARY CRITICAL CARE & SLEEP MEDICINE
ORAL IFETROBAN IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) No dispute reported 06/30/2026 1242141244